Skip to main content

Table 2 Third-line treatment per study arm

From: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

  DC (%) D (%) p-value
No treatment 27 (40.3%) 34 (52.3%) 0.222
Chemotherapy 28 (41.8%) 28 (43.1%) 0.999
EGFR-TKIs* 12 (17.9%) 3 (4.6%) 0.026
  1. *Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor